RespireRx Pharmaceuticals Inc (RSPI)

[myostrain]

The past few years have seem to shown that financing would be done at a time which is prudent, unfortunately with the current financial climite, one could ponder that they have been trying to get a financing but have not been able to secure it.

As much as I'd like to think that a pipe or financing of some sort not being done by this point could be a positive, I don't think it is something to put much weight into.

As far as deals go, Cortex has gone to lengths to analyze the markets for RD and with RD alone should garner enough data for any interested companies for greater than 10 million front loaded into a deal.

I would wager that the analysis that developed 10million for upfronts took into account a very pessimistic scenario in addition to some deals that other companies attained.

Pain therapeutics regarding their signing with King Pharm, in addition to a great upfront of 150M also had King Pharm attain full cost responsibility for R+D.
This deal took place before any of the recent market crap started but maybe a deal with a well performing drug co could contain 15-50M upfront plus cost responsibility for R+D for RD.